These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26553676)

  • 1. Public Health Impact After the Introduction of PsA-TT: The First 4 Years.
    Diomandé FV; Djingarey MH; Daugla DM; Novak RT; Kristiansen PA; Collard JM; Gamougam K; Kandolo D; Mbakuliyemo N; Mayer L; Stuart J; Clark T; Tevi-Benissan C; Perea WA; Preziosi MP; Marc LaForce F; Caugant D; Messonnier N; Walker O; Greenwood B
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S467-72. PubMed ID: 26553676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
    Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
    Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
    Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
    Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal carriage in the African meningitis belt.
    MenAfriCar Consortium
    Trop Med Int Health; 2013 Aug; 18(8):968-78. PubMed ID: 23682910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.
    Diomandé FV; Yaméogo TM; Vannice KS; Preziosi MP; Viviani S; Ouandaogo CR; Keita M; Djingarey MH; Mbakuliyemo N; Akanmori BD; Sow SO; Zuber PL
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S459-66. PubMed ID: 26553675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
    Karachaliou A; Conlan AJ; Preziosi MP; Trotter CL
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S594-600. PubMed ID: 26553693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.
    Vetter V; Baxter R; Denizer G; Sáfadi MA; Silfverdal SA; Vyse A; Borrow R
    Expert Rev Vaccines; 2016 May; 15(5):641-58. PubMed ID: 26651380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
    Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
    Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.